AstraZeneca PLC closed 21.95% short of its 52-week high of £133.88, which the company reached on September 3rd.

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

This was the ADR's fourth consecutive day of gains.

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

Compared to the aggregate P/E ratio of 27.38 in the Pharmaceuticals industry, AstraZeneca Inc. has a higher P/E ratio of ...

(Reuters) -AstraZeneca chief executive Pascal Soriot is considering moving the company's stock market listing to the United ...

Genetically engineered bacteria have been created that can convert polyethylene terephthalate (PET), the polymer plastic ...

The market, which was valued at $0.85 billion in 2024, is projected to grow to $0.91 billion in 2025, representing a compound annual growth rate CAGR of 7.2%. The growth during this historic period ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...